Anzeige
Mehr »
Login
Dienstag, 14.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
528 Leser
Artikel bewerten:
(2)

JZ Capital Partners Ltd - Result of AGM

Finanznachrichten News

JZ Capital Partners Ltd - Result of AGM

PR Newswire

JZ Capital Partners Limited
(a closed-ended collective investment scheme incorporated as a non-cellular company with limited liability under the laws of Guernsey with registration number 48761)

LEI Number: 549300TZCK08Q16HHU44
(The "Company")

6 July 2021

RESULT OF ANNUAL GENERAL MEETING

At the Annual General Meeting of the Company held on 6 July 2021, all Resolutions set out in the Annual General Meeting Notice sent to Shareholders dated 18 May 2021 were duly passed.

Details of the final voting position in respect of the valid proxies received by the Company should be read alongside the Notice and are noted below:

Ordinary ResolutionForAgainstWithheld
158,093,29700
258,093,29700
358,093,29700
457,881,9595,551205,787
5 (1)6,364,14017411,937
6 (1)6,364,14017411,937
7 (1)6,364,10321111,937
8(1)6,364,10321111,937
957,099,701993,5960
Extraordinary ResolutionForAgainstWithheld
1057,806,4680286,829

Note -A vote withheld is not a vote in law and has not been counted in the votes for and against a resolution.

(1) The proxy voting results in respect of Ordinary Resolutions 5 through to 8 have been counted in accordance with Article 14(17) of the Articles of Incorporation of the Company

The Special Business by Ordinary Resolution was also passed at the AGM, as detailed below:

11. SPECIAL BUSINESS BY ORDINARY RESOLUTION

To authorise the Directors in accordance with Article 4(8) of the Articles of Incorporation of the Company (the "Articles") to: (a) allot equity securities (as defined in the Articles) of the Company for cash; and (b) sell ordinary shares (as defined in the Articles) held by the Company as treasury shares for cash, as if Article 4(8) of the Articles did not apply to any such allotment or sale, provided that this power shall be limited to the allotment of equity securities for cash and the sale of treasury shares up to an aggregate amount of 7,747,417 ordinary shares, such authority to expire at the conclusion of the 2022 Annual General Meeting of the Company or on 31 July 2022, whichever is the earlier, save that the Company may before such expiry make any offer or agreement that would or might require equity securities to be allotted, or treasury shares to be sold, after such expiry and the Directors may allot equity securities, or sell treasury shares in pursuance of any such offer or agreement as if the power conferred hereby had not expired.

Ordinary ResolutionForAgainstWithheld
1150,609,2776,991,578492,442

Note -A vote withheld is not a vote in law and has not been counted in the votes for and against a resolution.

The Board is pleased with the overall level of support for all of the Resolutions set out in the Annual General Meeting Notice. It acknowledges, however, the level of votes against resolution 11 (the directors' general authority to allot equity securities). The Board intends to engage with certain of its shareholders in relation to this resolution but wishes to make clear that, whilst the Company reserves the right to issue further shares in the future, the resolution to seek authority from shareholders to do so was taken as it has been in previous years and on this occasion as a precautionary measure which is not at this time intended to be used.



Enquiries:

Company website: www.jzcp.com
Samuel Walden
Northern Trust International Fund Administration Services (Guernsey) Limited
Tel: +44 (0) 1481 745001
Email: SW171@ntrs.com

END

© 2021 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.